| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PRCT | Common Stock | Other | $0 | -660K | -100% | $0.00 | 0 | Nov 5, 2024 | By White Tailed Ptarmigan, LP | F1, F2 |
| transaction | PRCT | Common Stock | Other | $0 | -172K | -100% | $0.00 | 0 | Nov 5, 2024 | Mallard Fund, L.P | F2, F3, F4 |
| transaction | PRCT | Common Stock | Other | $0 | -62.9K | -100% | $0.00 | 0 | Nov 5, 2024 | Kestrel Fund, L.P. | F2, F4, F5 |
| transaction | PRCT | Common Stock | Sale | -$722K | -7.57K | -2.86% | $95.38 | 257K | Nov 5, 2024 | By The 2:22 DNA Trust | F4, F6, F7, F8, F9, F10 |
| transaction | PRCT | Common Stock | Sale | -$1.13M | -11.8K | -4.58% | $96.49 | 245K | Nov 5, 2024 | By The 2:22 DNA Trust | F6, F11 |
| transaction | PRCT | Common Stock | Sale | -$1.12M | -11.5K | -4.69% | $97.17 | 234K | Nov 5, 2024 | By The 2:22 DNA Trust | F6, F12 |
| transaction | PRCT | Common Stock | Sale | -$216K | -2.19K | -0.94% | $98.43 | 231K | Nov 5, 2024 | By The 2:22 DNA Trust | F6, F13 |
| transaction | PRCT | Common Stock | Sale | -$900K | -9.4K | -4.06% | $95.68 | 222K | Nov 6, 2024 | By The 2:22 DNA Trust | F6, F14 |
| transaction | PRCT | Common Stock | Sale | -$259K | -2.68K | -1.21% | $96.57 | 219K | Nov 6, 2024 | By The 2:22 DNA Trust | F6, F15 |
| transaction | PRCT | Common Stock | Sale | -$1.67M | -17.2K | -7.82% | $97.59 | 202K | Nov 6, 2024 | By The 2:22 DNA Trust | F6, F16 |
| transaction | PRCT | Common Stock | Sale | -$370K | -3.77K | -1.86% | $98.29 | 198K | Nov 6, 2024 | By The 2:22 DNA Trust | F6, F17 |
| transaction | PRCT | Common Stock | Sale | -$660K | -6.99K | -3.52% | $94.42 | 191K | Nov 7, 2024 | By The 2:22 DNA Trust | F6, F18 |
| transaction | PRCT | Common Stock | Sale | -$1.55M | -16.3K | -8.5% | $95.33 | 175K | Nov 7, 2024 | By The 2:22 DNA Trust | F6, F19 |
| transaction | PRCT | Common Stock | Sale | -$983K | -10.2K | -5.85% | $96.03 | 165K | Nov 7, 2024 | By The 2:22 DNA Trust | F6, F20 |
| transaction | PRCT | Common Stock | Sale | -$48.8K | -500 | -0.3% | $97.54 | 164K | Nov 7, 2024 | By The 2:22 DNA Trust | F6 |
| holding | PRCT | Common Stock | 6.87K | Nov 5, 2024 | Direct | F8, F9 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | On November 5, 2024, White Tailed Ptarmigan, LP distributed shares on a pro rata basis, for no consideration, including 51,245 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13. |
| F2 | CPMG, Inc. is the general partner and investment manager of each of White Tailed Ptarmigan, LP, Kestrel Fund, L.P. and Mallard Fund, L.P. (collectively, the "CPMG Funds"). Antal Desai, a member of the Issuer's board of directors and a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by the CPMG Funds. Mr. Desai disclaims beneficial ownership of the shares beneficially owned by the CPMG Funds except to the extent of any pecuniary interest therein. |
| F3 | On November 5, 2024, Mallard Fund, L.P. distributed all of its remaining shares on a pro rata basis, for no consideration, including 8,511 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13. |
| F4 | Includes shares previously held indirectly through White Tailed Ptarmigan, LP, which were distributed on a pro rata basis, for no consideration, on November 5, 2024, in a transaction exempt from Section 16 under Rules 16a-9 and 16a-13. |
| F5 | On November 5, 2024, Kestrel Fund, L.P. distributed all of its remaining shares on a pro rata basis, for no consideration, including 3,316 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13. |
| F6 | The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. |
| F7 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.64 to $95.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| F8 | Includes shares previously held indirectly through Mallard Fund, L.P., which were distributed on a pro rata basis, for no consideration, on November 5, 2024, in a transaction exempt from Section 16 under Rules 16a-9 and 16a-13. |
| F9 | Includes shares previously held indirectly through Kestrel Fund, L.P., which were distributed on a pro rata basis, for no consideration, on November 5, 2024, in a transaction exempt from Section 16 under Rules 16a-9 and 16a-13. |
| F10 | Mr. Desai and his spouse serve as co-trustees of The 2:22 DNA Trust. Mr. Desai disclaims beneficial ownership of the shares beneficially owned by The 2:22 DNA Trust except to the extent of any pecuniary interest therein. |
| F11 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.91 to $96.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| F12 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.91 to $97.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| F13 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.94 to $98.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| F14 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.07 to $96.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| F15 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.07 to $97.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| F16 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.07 to $98.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| F17 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.09 to $98.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| F18 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.75 to $94.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| F19 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.78 to $95.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| F20 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.78 to $96.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |